PUBLIC BIOCAD ZAO is one of the world’s few full-cycle drug development and manu- facturing companies. Its efforts span new-molecule discovery and large-scale commercial drug production and marketing, which has made BIOCAD one of Russia’s leading and most innovative biotechnology companies. To support this end-to-end business model, BIOCAD knew it needed a connected IT architecture. Specifically, the company sought to harmonize all aspects of business management, from medicine labeling and traceability to operational and financial planning and analysis. BIOCAD hoped that a unified foundation for business would help the company increase efficiency and reduce costs amid plans for global expansion – while enabling the company’s COVID-19 vaccine efforts in Russia. BIOCAD: Bringing Gr

Join for free to read